Literature DB >> 31243362

Immune evasion before tumour invasion in early lung squamous carcinogenesis.

Céline Mascaux1,2,3,4,5,6, Mihaela Angelova7,8,9,10,11, Angela Vasaturo7,8,9,10, Jennifer Beane12, Kahkeshan Hijazi12, Geraldine Anthoine13, Bénédicte Buttard7,8,9,10, Françoise Rothe14, Karen Willard-Gallo15, Annick Haller16,17, Vincent Ninane18, Arsène Burny19, Jean-Paul Sculier13, Avi Spira12, Jérôme Galon20,21,22,23.   

Abstract

Early detection and treatment are critical for improving the outcome of patients with cancer1. Understanding the largely uncharted biology of carcinogenesis requires deciphering molecular processes in premalignant lesions, and revealing the determinants of the intralesional immune reaction during cancer development. The adaptive immune response within tumours has previously been shown to be strongest at the earliest stage of carcinoma2,3. Here we show that immune activation and immune escape occur before tumour invasion, and reveal the relevant immune biomarkers of the pre-invasive stages of carcinogenesis in the lung. We used gene-expression profiling and multispectral imaging to analyse a dataset of 9 morphological stages of the development of lung squamous cell carcinoma, which includes 122 well-annotated biopsies from 77 patients. We identified evolutionary trajectories of cancer and immune pathways that comprise (1) a linear increase in proliferation and DNA repair from normal to cancerous tissue; (2) a transitory increase of metabolism and early immune sensing, through the activation of resident immune cells, in low-grade pre-invasive lesions; (3) the activation of immune responses and immune escape through immune checkpoints and suppressive interleukins from high-grade pre-invasive lesions; and, ultimately, (4) the activation of the epithelial-mesenchymal transition in the invasive stage of cancer. We propose that carcinogenesis in the lung involves a dynamic co-evolution of pre-invasive bronchial cells and the immune response. These findings highlight the need to develop immune biomarkers for early detection as well as immunotherapy-based chemopreventive approaches for individuals who are at high risk of developing lung cancer.

Entities:  

Mesh:

Year:  2019        PMID: 31243362     DOI: 10.1038/s41586-019-1330-0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  25 in total

1.  Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin.

Authors:  D P SLAUGHTER; H W SOUTHWICK; W SMEJKAL
Journal:  Cancer       Date:  1953-09       Impact factor: 6.860

Review 2.  Pulmonary preinvasive neoplasia.

Authors:  K M Kerr
Journal:  J Clin Pathol       Date:  2001-04       Impact factor: 3.411

Review 3.  The biology and management of non-small cell lung cancer.

Authors:  Roy S Herbst; Daniel Morgensztern; Chris Boshoff
Journal:  Nature       Date:  2018-01-24       Impact factor: 49.962

4.  An actuarial approach to comparing early stage and late stage lung cancer mortality and survival.

Authors:  Sara W Goldberg; James L Mulshine; Dale Hagstrom; Bruce S Pyenson
Journal:  Popul Health Manag       Date:  2010-02       Impact factor: 2.459

5.  Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.

Authors:  Jérôme Galon; Anne Costes; Fatima Sanchez-Cabo; Amos Kirilovsky; Bernhard Mlecnik; Christine Lagorce-Pagès; Marie Tosolini; Matthieu Camus; Anne Berger; Philippe Wind; Franck Zinzindohoué; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Franck Pagès
Journal:  Science       Date:  2006-09-29       Impact factor: 47.728

6.  Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.

Authors:  Bernhard Mlecnik; Marie Tosolini; Amos Kirilovsky; Anne Berger; Gabriela Bindea; Tchao Meatchi; Patrick Bruneval; Zlatko Trajanoski; Wolf-Herman Fridman; Franck Pagès; Jérôme Galon
Journal:  J Clin Oncol       Date:  2011-01-18       Impact factor: 44.544

Review 7.  Future directions in cancer prevention.

Authors:  Asad Umar; Barbara K Dunn; Peter Greenwald
Journal:  Nat Rev Cancer       Date:  2012-11-15       Impact factor: 60.716

8.  In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.

Authors:  Franck Pagès; Amos Kirilovsky; Bernhard Mlecnik; Martin Asslaber; Marie Tosolini; Gabriela Bindea; Christine Lagorce; Philippe Wind; Florence Marliot; Patrick Bruneval; Kurt Zatloukal; Zlatko Trajanoski; Anne Berger; Wolf-Herman Fridman; Jérôme Galon
Journal:  J Clin Oncol       Date:  2009-10-26       Impact factor: 44.544

Review 9.  The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures.

Authors:  Jérôme Galon; Helen K Angell; Davide Bedognetti; Francesco M Marincola
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

10.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.

Authors:  Gabriela Bindea; Bernhard Mlecnik; Marie Tosolini; Amos Kirilovsky; Maximilian Waldner; Anna C Obenauf; Helen Angell; Tessa Fredriksen; Lucie Lafontaine; Anne Berger; Patrick Bruneval; Wolf Herman Fridman; Christoph Becker; Franck Pagès; Michael R Speicher; Zlatko Trajanoski; Jérôme Galon
Journal:  Immunity       Date:  2013-10-17       Impact factor: 31.745

View more
  90 in total

Review 1.  Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironment.

Authors:  Samuel S Widodo; Ryan A Hutchinson; Yitong Fang; Stefano Mangiola; Paul J Neeson; Phillip K Darcy; Alexander D Barrow; Christopher M Hovens; Marija Dinevska; Stanley S Stylli; Theo Mantamadiotis
Journal:  Cancer Immunol Immunother       Date:  2021-01-03       Impact factor: 6.968

2.  Overview of Lung Cancer Immunotherapy.

Authors:  Miguel F Sanmamed; Iñaki Eguren-Santamaria; Kurt A Schalper
Journal:  Cancer J       Date:  2020 Nov/Dec       Impact factor: 3.360

Review 3.  Cancer Immunoprevention: Current Status and Future Directions.

Authors:  Mahsa Keshavarz-Fathi; Nima Rezaei
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2021-02-27       Impact factor: 4.291

4.  Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer.

Authors:  Bernhard Mlecnik; Carlo Bifulco; Gabriela Bindea; Florence Marliot; Alessandro Lugli; J Jack Lee; Inti Zlobec; Tilman T Rau; Martin D Berger; Iris D Nagtegaal; Elisa Vink-Börger; Arndt Hartmann; Carol Geppert; Julie Kolwelter; Susanne Merkel; Robert Grützmann; Marc Van den Eynde; Anne Jouret-Mourin; Alex Kartheuser; Daniel Léonard; Christophe Remue; Julia Y Wang; Prashant Bavi; Michael H A Roehrl; Pamela S Ohashi; Linh T Nguyen; SeongJun Han; Heather L MacGregor; Sara Hafezi-Bakhtiari; Bradly G Wouters; Giuseppe V Masucci; Emilia K Andersson; Eva Zavadova; Michal Vocka; Jan Spacek; Lubos Petruzelka; Bohuslav Konopasek; Pavel Dundr; Helena Skalova; Kristyna Nemejcova; Gerardo Botti; Fabiana Tatangelo; Paolo Delrio; Gennaro Ciliberto; Michele Maio; Luigi Laghi; Fabio Grizzi; Tessa Fredriksen; Bénédicte Buttard; Lucie Lafontaine; Daniela Bruni; Anastasia Lanzi; Carine El Sissy; Nacilla Haicheur; Amos Kirilovsky; Anne Berger; Christine Lagorce; Christopher Paustian; Carmen Ballesteros-Merino; Jeroen Dijkstra; Carlijn van de Water; Shannon van Lent-van Vliet; Nikki Knijn; Ana-Maria Muşină; Dragos-Viorel Scripcariu; Boryana Popivanova; Mingli Xu; Tomonobu Fujita; Shoichi Hazama; Nobuaki Suzuki; Hiroaki Nagano; Kiyotaka Okuno; Toshihiko Torigoe; Noriyuki Sato; Tomohisa Furuhata; Ichiro Takemasa; Kyogo Itoh; Prabhu S Patel; Hemangini H Vora; Birva Shah; Jayendrakumar B Patel; Kruti N Rajvik; Shashank J Pandya; Shilin N Shukla; Yili Wang; Guanjun Zhang; Yutaka Kawakami; Francesco M Marincola; Paolo A Ascierto; Bernard A Fox; Franck Pagès; Jérôme Galon
Journal:  J Clin Oncol       Date:  2020-09-08       Impact factor: 44.544

Review 5.  Blocking inflammation to improve immunotherapy of advanced cancer.

Authors:  Antonio Macciò; Clelia Madeddu
Journal:  Immunology       Date:  2019-12-27       Impact factor: 7.397

6.  Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma.

Authors:  Jason Yongsheng Chan; Jing Quan Lim; Joe Yeong; Vinod Ravi; Peiyong Guan; Arnoud Boot; Timothy Kwang Yong Tay; Sathiyamoorthy Selvarajan; Nur Diyana Md Nasir; Jie Hua Loh; Choon Kiat Ong; Dachuan Huang; Jing Tan; Zhimei Li; Cedric Chuan-Young Ng; Thuan Tong Tan; Mikio Masuzawa; Ken Wing-Kin Sung; Mohamad Farid; Richard Hong Hui Quek; Ngian Chye Tan; Melissa Ching Ching Teo; Steven George Rozen; Patrick Tan; Andrew Futreal; Bin Tean Teh; Khee Chee Soo
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

7.  Genes and pathways monotonically dysregulated during progression from normal through leukoplakia to gingivo-buccal oral cancer.

Authors:  Debodipta Das; Arindam Maitra; Chinmay K Panda; Sandip Ghose; Bidyut Roy; Rajiv Sarin; Partha P Majumder
Journal:  NPJ Genom Med       Date:  2021-05-12       Impact factor: 8.617

8.  Experimental study on preparation and anti-tumor efficiency of nanoparticles targeting M2 macrophages.

Authors:  Zheng Zeng; Yu Liu; Qinglian Wen; Yixian Li; Jing Yu; Qiang Xu; Wenwu Wan; Yu He; Chen Ma; Yan Huang; Helin Yang; Ou Jiang; Fuyu Li
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

Review 9.  Lung Cancer and Immunity Markers.

Authors:  Raymond J Lim; Bin Liu; Kostyantyn Krysan; Steven M Dubinett
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-08-20       Impact factor: 4.254

10.  An Improved Murine Premalignant Squamous Cell Model: Tobacco Smoke Exposure Augments NTCU-Induced Murine Airway Dysplasia.

Authors:  Lori D Dwyer-Nield; Debbie G McArthur; Meredith A Tennis; Daniel T Merrick; Robert L Keith
Journal:  Cancer Prev Res (Phila)       Date:  2020-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.